Clinical Research Directory
Browse clinical research sites, groups, and studies.
RFA Plus Carrizumab vs Carrizumab Alone for HCC
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Summary
The study aims to find whether patients with advanced HCC can get more benefits from RFA +PD-1 immunosuppressant (carrizumab) compared with carrizumab alone, considering with the result of PFS.
Official title: Radiofrequency Ablation Plus Carrizumab vs Carrizumab Alone for Moderate or Advanced Hepatocellular Carcinoma: A Real World Study
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2020-08-01
Completion Date
2026-12-30
Last Updated
2020-07-08
Healthy Volunteers
Yes
Interventions
radiofrequency ablation
take advantage of RFA to destroy hepatocellular carcinoma by high temperature
Locations (1)
the Second Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, China